We conducted a randomized, open-labeled clinical trial to compare the tolerability and efficacy of amphotericin B deoxycholate, prepared in 5% dextrose or Intralipid (Kabi Pharmacia, SaintQuentin-en-Yvelines, France), in the treatment of AIDS-associated cryptococcal meningitis in Burundi. Forty-four patients were assigned to receive amphotericin B/dextrose (0.7 mg/[kg-d]) for 14 days; the dose was then reduced to 1 mg/kg every other day for 28 days (infused over 6 hours). Forty-six patients were assigned to receive Intralipid/amphotericin B at a 50% higher dosage (1 mg/lkg-d]) for 14 days; the dose was then reduced to 1.5 mg/kg every other day for 28 days (infused over 2 hours). Intralipid significantly decreased the incidence of fever (P = .02) and chills (P = .0001) related to the infusion of amphotericin B deoxycholate. Analysis of the time to the onset of increased levels of serum creatinine (creatinine level, > 150 p,mollL)showed that Intralipidl amphotericin B was more nephrotoxic (P = .03). The percentage of patients who were clinically cured or had improvement in their conditions and successful mycological outcome was similar in both therapeutic groups, but analysis of the time to the first negative cerebrospinal fluid culture showed a nearly significant difference that favored Intralipid/amphotericin B (P = .07). Intralipid reduced the infusion-related toxicity of amphotericin B deoxycholate without altering its antifungal efficacy but did not confer substantial benefit against renal toxicity that would allow the unitary dosage of amphotericin B deoxycholate to be increased safely.
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Cryptococcosis occurs most frequently in immunocompromised hosts, especially patients with AIDS. In Western countries, '"-' 6%-10% of patients with AIDS develop cryptococcal meningitis [1] ; however, in Central Africa, where Cryptococcus neoformans is the second most common pathogen isolated from the blood of febrile patients, the incidence of cryptococcal meningitis is even higher [2] .
Among patients with AIDS and cryptococcal meningitis, 15%-30% die while receiving induction therapy, and most of these deaths occur during the first several weeks of treatment [3, 4] . Fluconazole has been shown to be the drug of choice for maintenance therapy [5] , but the optimal initial therapy is still controversial. The current trend is to administer an aggressive initial regimen consisting of amphotericin B at a high dose (0.7 -1 mg/[kg· dJ) [1, 6, 7] , with or without flucytosine.
The conventional formulation of amphotericin B, amphotericin B deoxycholate dissolved in 5% dextrose (amphotericin B/dextrose), is associated with significant nephrotoxicity and infusion-related morbidity (i.e., fever and chills). Various investigational formulations of amphotericin B, including AmBisome (Vestar, San Dimas, CA), amphotericin B lipid complex (ABLC; Abe1cet, Liposome Company, Princeton, NJ), and amphotericin B colloidal dispersion (ABCD; Amphocil, Sequus Pharmaceuticals, Menlo Park, CA) that have been designed primarily to reduce the drug's toxicity, have entered clinical trials. Data on the use of these formulations in patients with AIDS and cryptococcosis are limited [8, 9] , and they have not been compared to conventional amphotericin B deoxycholate in large prospective trials. Furthermore, their high cost precludes widespread use.
Intralipid (Kabi Pharmacia, Saint-Quentin-en-Yvelines, France) is a lipidic emulsion that is commercially available for parenteral nutrition. It has been shown that amphotericin B deoxycholate that has been directly emulsified in 20% Intralipid (Intralipid/amphotericin B) induced fever and chills and decreased creatinine clearance less often in neutropenic patients than did amphotericin B/dextrose [10] , and that it remained effective in the treatment of systemic candidiasis [11] . We showed that Intralipid/amphotericin B was less toxic than and as efficient as amphotericin B/dextrose in mice with experimental cryptococcosis and that Intralipid enhanced the therapeutic activity of amphotericin B by allowing larger doses of the drug to be infused [12] . We conducted a recent pilot study in patients with AIDS and cryptococcosis [13] and demonstrated that Intralipid/amphotericin B, given in a dosage of 1 mg/tkg : d), was acceptably tolerated; this regimen was associated with a mycological cure rate of 62%. However, increasing the dosage of this formulation to 1.5 mg/Ikg-d) led to nephrotoxicity in five of six patients.
We initiated a randomized, open-labeled clinical trial to compare amphotericin B/dextrose with Intralipid/amphotericin B in terms of efficacy and tolerability when either agent was used as primary therapy for cryptococcal meningitis in patients with AIDS. This trial was conducted at the University Kamenge Hospital in Bujumbura, Burundi, where amphotericin B deoxycholate is the only drug available for the treatment of systemic fungal infections.
Methods
Study population. The criteria for enrollment in this study included HIV infection, as documented by positive serology; age,~18 years; and a CSF culture positive for C. neoformans.
Patients could be included on the basis of preliminary evidence of acute cryptococcal meningitis (i.e., a positive CSF India ink preparation or the presence of cryptococcal antigen in CSF [Crypto Test Latex Agglutination, Biomedical Diagnostics, Marne-La-Vallee, France]). However, a culture of CSF had to be positive for the patient to be assessable. Cases of cryptococcosis were considered to be either initial episodes or relapses following successful treatment. Patients were excluded if they had received> 1 mg/kg of intravenous amphotericin B within 1 week before entry into the study or had a Kamofsky score of~20. Treatment with other systemic antifungal drugs was not allowed during the study.
Treatment. Amphotericin B deoxycholate was obtained from Bristol Myers Squibb (Paris La Defense, France), and Intralipid was obtained from Kabi Pharmacia.
Infusions were prepared as follows: amphotericin B/dextrose was prepared according to the usual recommendations; the amount of amphotericin B deoxycholate needed for each treatment was diluted in 5% glucose in a final volume of 500 mL. An initial preparation of Intralipid/amphotericin B was obtained by adding 10 mL of 20% Intralipid directly to the vial containing 50 mg of amphotericin B deoxycholate. The vial was vigorously shaken by hand until a homogeneous yellow emulsion was obtained, and the total amount of Intralipid/amphotericin B needed to treat each patient was further diluted in 20% Intralipid to obtain a final volume of 125 mL. The mixture was used immediately after preparation.
Treatment was initiated after a l-mg test dose had been infused over 30 minutes, with no evidence of side effects. Treatment was given daily for 14 days; the unitary doses were 0.7 mg/kg for amphotericin B/dextrose and 1 mg/kg for Intralipid/amphotericin B. These formulations were then given every other day for 28 days at the respective unitary doses of 1 mg/kg and 1.5 mg/kg. Amphotericin B/dextrose and Intralipid/ amphotericin B were infused over 6 hours and 2 hours, respectively.
Evaluation. Patients were hospitalized during therapy. After a baseline assessment, patients were evaluated every week for 6 weeks. At each visit, a physical examination was performed, and any adverse event was rated and recorded. Levels of serum electrolytes, hemoglobin, and creatinine, the differential count, and liver function were monitored to ensure the patient's safety and assess the toxicity of the treatments. Infusion-related side effects (fever, chills, rash, nausea, or abnormal blood pressure) were monitored during each infusion and for 2 hours afterwards.
Fever was defined as an increase of ;-::1°C in body temperature between the temperature measured before infusion and the highest temperature reported during infusion and during the subsequent 2-hour period. To reduce the severity of fever and chills, 1 g of aspirin (Synthelabo France, Meudon-La-Foret, France) and/or 100 mg of hydrocortisone hemisuccinate (Distriphar, Montrouge, France) were administered when needed. These drugs were also given as preventive treatment to patients who had experienced fever or chills during a previous infusion.
Response to therapy was assessed clinically and mycologically. Clinical cure was defined as the complete resolution of symptoms; clinical improvement, as the resolution of some, but not all clinical symptoms; and clinical failure, as no change in the patient's condition or the emergence of new clinical signs that were not related to toxicity or to another opportunistic infection. The relationship between a patient's death and cryptococcosis was established by an independent blinded physician. Samples of CSF were obtained by lumbar puncture once a week. The mycological outcome was considered successful if culture of at least the last available CSF sample was negative. One of the authors (P.A. or A.N.) ascertained that the information recorded on case report forms was accurate and conformed with the raw data in the patients' files.
Study design. To analyze the efficacy of the two regimens, we compared the two groups in terms of the rates of successful treatment. We hypothesized that if amphotericin B/dextrose was no more than 25% more effective than Intralipid/amphotericin B in the treatment of acute cryptococcal meningitis in patients with AIDS (as indicated by successful sterilization of CSF cultures), then Intralipid/amphotericin B could be considered a useful agent for treating cryptococcal meningitis.
We further postulated that treatment with amphotericin B/ dextrose would result in sterilization of the CSF in 70% of the patients by the end of the 6-week regimen, and we used a onesided test of significance with an a level of 0.05 and a power of 80% to detect a response rate that was 20% lower for patients treated with Intralipid/amphotericin B than for patients treated with amphotericin B/dextrose. Therefore, 80 assessable patients (40 assigned to each treatment arm) were scheduled to be enrolled (a total of 90 patients were finally enrolled). Patients were randomly assigned to open-labeled administration of either amphotericin B/dextrose em 1996; 23 (September) or Intralipid/amphotericin B at a 1:1 ratio. Patients were randomized by means of sealed envelopes distributed at the study site (Kamenge Hospital) and were stratified for the presence or absence of relapse of cryptococcal meningitis.
Statistical analysis. We considered two analyzable populations. According to the intent-to-treat principle, all patients were included in the study of safety, but only patients with a positive CSF culture were included in the efficacy analysis. The treatment groups were compared by means of Wilcoxon's rank sum test for the quantitative variables and by means of the X 2 test for the categorical variables (both tests were two sided; a = 0.05). In addition, survival was analyzed to compare treatment groups on the basis of mycological outcome, mortality, and renal toxicity. The Kaplan-Meier method with the log-rank test was used when the observed survival times were continuous (i.e., death could occur at any time). The proportional hazards model with an exact calculation of survival probability was used when the times that endpoints were assessed were preset. To evaluate alterations in hematologic and biochemical parameters under treatment, analyses of covariance (ANCOVA) were performed on ranks calculated on changes from baseline. The model contained baseline, treatment, and time-of-assessment effects. Values obtained weekly or daily were considered repeated measures.
Results
Study population. Ninety patients were enrolled in the study over 24 months. Of these 90 patients, 44 were assigned to receive amphotericin B/dextrose and 46 were assigned to receive Intralipid/amphotericin B. One patient in the Intralipid/ amphotericin B group initially developed renal failure (creatinine clearance, 7 mL/min) but was retained in the study for the safety and efficacy analyses. Nine patients (five who received amphotericin B/dextrose and four who received Intralipid/amphotericin B could not be included in the efficacy analysis because baseline CSF cultures were negative for C. neoformans. However, these patients were included in the analysis of toxicity. The groups were well matched at baseline in terms of demographic characteristics and clinical signs and symptoms of cryptococcal disease (table 1) . There was no difference at baseline between the groups with respect to weight, Kamofsky scores, hemoglobin levels, neutrophil counts, platelet counts, and albumin levels, but there were significant differences with respect to serum creatinine levels and creatinine clearance rates (table 1). The CD4 cell counts were not available, but 71% of the subjects had a history of illness that could be related to HIV infection, indicating underlying immunosuppression.
Administration oftreatment. The median duration oftherapy was 26 days in both groups. The mean daily dose of amphotericin B deoxycholate administered was 47% higher in the Intralipid/amphotericin B group than in the other group (0.85 mg/lkg-d] vs. 1.25 mg/lkg : d], respectively) due to differences in the assigned dosage regimens, as planned by the protocol. In each group, the mean daily dose actually administered represented 97.6% of the mean daily dose prescribed by the protocol. The dose was lowered for four patients (three in the Intralipid/amphotericin B group and one in the amphotericin B/dextrose group) because they developed nephrotoxicity. Three patients (one in the Intralipid/ amphotericin B group and two in the amphotericin B/dextrose group) requested to be withdrawn from the study before therapy was completed. Culture results for CSF sampled on day 42 were available for all but three surviving patients. The difference in success rates between the treatment groups was not significant (P = .16); Intralipid/amphotericin B was associated with a cure rate that was 15.2% higher than that for amphotericin B/ dextrose (95% CI = -5.8-36.2). Analysis of the time to the first negative CSF culture showed a nearly significant difference between treatment groups (figure 1) (P = .07, likelihood ratio test; relative risk = 1.68; 95% CI = 0.952-2.953). Analysis of the time to death showed no significant difference between treatment groups (P = .72, log-rank test).
Toxicity. No death was attributed to adverse effects oftherapy. Infusion-related toxicity mainly consisted of fever and chills. The results are expressed as the number of patients who presented with symptoms at least once over the 42 days of therapy (table 3) . A significant difference between the groups was found for chills (P = .0001) and for fever (P = .02), with amphotericin B/dextrose being more toxic than Intralipid/ amphotericin B. Nausea was rarely observed and was a variable that was independent of the type of treatment.
There was a significant difference between the two groups in terms of the numbers of patients treated with aspirin Finally, since baseline creatinine levels were higher for patients in the Intralipid/amphotericin B group, changes from baseline values to values on each day of assessment were also calculated to adjust the comparison for baseline: Intralipid/ amphotericin B was more nephrotoxic than was amphotericin B/dextrose by ANCOVA on ranks (P = .012). Kalemia was not significantly influenced by treatment.
There were no severe (~grade 3) episodes of neutropenia, thrombocytopenia, or hepatic toxicity. Hemoglobin levels t At least one episode. decreased significantly from baseline in both groups, and the ANCOVA on ranks (based on changes from baseline on days 14 and 42) showed that these decreases were more pronounced in the Intralipid/amphotericin B group (P = .033). At the end of treatment (day 42), the median hemoglobin value had decreased from 10.8 g/dL (range, 5.7-13.2 g/dL) on day 0 to 9.3 g/dL (range, 5.5-13.2 g/dL) on day 42 in patients treated with amphotericin B/dextrose and from 11.2 g/dL (range, 7-16.5 g/dL) on day 0 to 7.9 g/dL (range, 4.0-12.5 g/dL) on day 42 in patients treated with Intralipid/amphotericin B.
infected patients with oral candidiasis [16] or cryptococcal meningitis [13] . The only comparative study was performed in patients with oral candidiasis, and the duration of therapy was short (5 days). To the best of our knowledge, no randomized prospective study comparing the efficacy and toxicity of Intralipid/amphotericin B with the efficacy and toxicity of amphotericin B/dextrose in the treatment of systemic fungal infection has been reported. The primary objectives of our comparative study were to investigate whether IntralipidJamphotericin B would be less toxic than and at least as effective as amphotericin B/dextrose in the treatment of cryptococcal meningitis. In a preliminary pilot study of patients with cryptococcal meningitis, we found that Intralipid/amphotericin B was well tolerated, provided that the daily dosage did not exceed 1 mg/kg [13] . Thus, the daily dose of Intralipid/amphotericin B for the present study was 150% that of the dose of amphotericin B/dextrose (0.7 mg/kg).
In our study, the clinical manifestations at presentation were concordant with those reported previously for patients with AIDS [8, 17] . Headache and fever were the most common symptoms. Our study was performed in severely ill patients, one-third of whom had initially altered levels of consciousness. CD4 cell counts were not determined in this study. However, 71% of the patients had a history of illness that could be related to HIV infection, suggesting that most patients were severely immunosuppressed.
Intralipid clearly reduced the infusion-related toxicity of amphotericin B deoxycholate in spite of a shorter infusion time. This reduction in side effects allowed decreased use of antipyretics, thereby simplifying the administration and monitoring of therapy. However, the incidence of fever and chills among our patients remained higher than that (< 1%) reported in previous studies on the treatment of systemic [11] and oral candidiasis [16] .
Intralipid/amphotericin B appeared to be more nephrotoxic than amphotericin B/dextrose at the doses used in this study. The two therapeutic groups differed in terms of levels of serum creatinine on day 0; however, changes from baseline, assessed by ANCOV A on ranks in order to adjust the comparison, were significantly more pronounced in patients treated with Intralipid/amphotericin B than in those treated with amphotericin B/ Although the treatment of cryptococcosis in patients with AIDS has been extensively investigated, the best regimen for induction therapy has not yet been determined [14] . Most investigators agree that initial therapy with amphotericin B at a dose of O. 7-1 mg/tkg : d) is appropriate, particularly in severe forms of the disease. However, the associated nephrotoxicity often limits the duration of treatment [15] , and the daily dose of the drug is often influenced more by alterations in renal function than by the response of the patient to therapy. Therefore, improvement in the drug's tolerability is urgently needed.
Encouraging results in terms of tolerability and therapeutic efficacy have been reported when Intralipid/amphotericin B is given to patients with systemic candidiasis [11] and to HIV- In terms of renal tolerance, Intralipidlamphotericin B clearly differed from AmBisome and ABLC, which are well tolerated in patients with preexisting renal failure. In a study by Coker et al. [8] , the mean daily dose of AmBisome was 3 mg/kg, but the maximum rise in creatinine levels was 130% from baseline, and no change in serum creatinine levels was noted with a cumulative 4g-dose of AmBisome. In a study by Chopra et al. [18] , 26 patients received AmBisome because of nephrotoxicity caused by conventional amphotericin B, and renal function improved during therapy with this formulation. In a cohort of patients treated with ABLC because of renal dysfunction (creatinine level, > 220 f.lmol/L), a significant trend towards declining serum creatinine levels was found at the end of therapy. The renal toxicity profiles of Intralipid/amphotericin B, ABLC, and AmBisome parallel the differences in LD so measured in mice given each of these formulations [12, 19, 20] .
The present study also confirmed the potential hematologic toxicity ofIntralipidiamphotericin B, which we have previously described [13] . Anemia was noted in both groups, but was more marked in patients treated with Intralipid/amphotericin B who received a higher total dose of amphotericin B deoxycholate. Hematologic toxicity, particularly anemia, has been described in patients who received conventional amphotericin B.
Decreases in hematocrit of > 10 units occurred during 76% of the treatment courses described by Utz et al. [21] . Mechanisms of amphotericin B-induced anemia have not been completely elucidated; however, hemolysis, decreased erythropoietin production, and direct toxic effects on progenitor cells have been discussed [22] . In our population, additional factors such as poor clinical condition, malnutrition, and chronic parasitic diseases could explain the high incidence of anemia.
The cure rate (54%) obtained with amphotericin B/dextrose compared favorably with that reported in previous studies. In the trial reported by Saag et al. [4] , the CSF sterilization rate reported for conventional amphotericin B was 40%. However, the mean dosage of the drug was low (0.45 mg/[kg· dJ), which could explain the poor response rate. Larsen and colleagues [23] found that the outcomes for all six patients who received amphotericin B (0.7 mg/[kg· dJ) plus flucytosine (150 mg/[kg· dJ) were successful. The number of patients included in this study was small, but the data suggest that the dosage of amphotericin B/dextrose selected for the present study was appropriate. More recently results from ACTG (AIDS Clinical Trials Group) 159 confirm the value of this regimen [24] .
In the present study, the difference in mycological outcome between the two treatment arms was not statistically significant, but there was a trend in favor of Intralipid/amphotericin B. Since experimental data suggest that lipid formulations do not increase the efficacy of amphotericin B against fungi per se, the better mycological outcome among patients treated with amphotericin B may be related to the higher dose infused.
Whether use of the same dosage of amphotericin B deoxycholate in both groups would have shown that the two formulations were of similar efficacy, with less renal toxicity in patients treated with Intralipid/amphotericin B, remains undetermined. However, the differences between the two regimens in terms of both efficacy and toxicity suggest that Intralipid/arnphotericin B, unlike other lipidic formulations of amphotericin B, does not allow use of doses of amphotericin B deoxycholate that are larger than those of conventional amphotericin B/dextrose.
In conclusion, Intralipid reduced the infusion-related toxicity of amphotericin B deoxycholate without altering its antifungal efficacy but did not confer a substantial benefit in terms of protection against the renal toxicity of the drug that would allow the unitary dosage of amphotericin B to be increased safely. The benefit associated with the use of Intralipid/amphotericin B therefore remains limited to the increased immediate tolerability of this formulation and to the possibility of a shorter infusion time, thereby simplifying the treatment of patients. This benefit may be especially important in developing countries, where no drug other than amphotericin B is available to treat systemic fungal infections.
